Loading...
•
Dec 31, 2020
Generation Bio Q4 2020 Earnings Report
Reported fourth quarter and full year 2020 financial results.
Key Takeaways
Generation Bio reported its Q4 and full year 2020 financial results, highlighting a strong cash position of $262.3 million at the end of 2020, bolstered by net proceeds from a follow-on offering, which funds key milestones into 2024. The company also remains on track to begin IND-enabling studies for hemophilia A in 2021.
Raised $225.4 million in gross proceeds from follow-on offering in January 2021.
Appointed Ron Cooper to Board of Directors in February 2021.
Announced preclinical data supporting development candidate selection for hemophilia A program.
Cash, cash equivalents and marketable securities were $262.3 million as of December 31, 2020.
Generation Bio
Generation Bio
Forward Guidance
Generation Bio anticipates several milestones in 2021, including NHP factor VIII expression data for hemophilia A, NHP factor IX expression, durability and redosing data, initiation of IND-enabling studies for phenylketonuria (PKU), and preclinical data for Gaucher disease and Wilson disease, as well as preclinical data for expression of therapeutic antibodies.
Positive Outlook
- NHP factor VIII expression data for hemophilia A development candidate
- NHP factor IX expression, durability and redosing data
- Initiation of IND-enabling studies for phenylketonuria (PKU)
- Preclinical data for Gaucher disease
- Preclinical data for Wilson disease